MGG Group Co., Inc., Chevy Chase Clinical Research
Chevy Chase, Maryland, United States
Doctor in Friendship Village, Maryland
5550 Friendship Blvd t90, Chevy Chase, MD 20815
About MGG Group Co., Inc., Chevy Chase Clinical Research
"Chevy Chase Clinical Research is the largest research center of its kind in the region with approximately 90,000 patients in its database. Established in 1996 as part of Affiliated Research Centers, it is now an independent research site. Under the direction of Medical Director Dr. Aamir Ali, more than 300 studies have been conducted in all areas of Gastroenterology and some areas of Internal Medicine."
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at MGG Group Co., Inc., Chevy Chase Clinical Research
During the past decade, MGG Group Co., Inc., Chevy Chase Clinical Research conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 9 clinical trials were completed, i.e. on
average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 6 clinical trials were completed. i.e. 300%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen
2006-10-04
2016-04-12
Completed
24,081
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
2007-05-01
2010-05-01
Terminated
661
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension
2006-09-01
2009-08-01
Completed
849
Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin
2012-07-01
2013-05-01
Completed
354
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
2013-10-29
2017-07-10
Completed
2,139
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
2013-10-29
2017-03-22
Terminated
16,784
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
2013-10-29
2017-04-03
Terminated
10,564
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "MGG Group Co., Inc., Chevy Chase Clinical Research" #1 sponsor was "Pfizer" with 7 trials, followed by "Galapagos NV" with 3 trials
sponsored, "Allergan" with 1 trials sponsored, "Bausch Health Americas, Inc." with 1 trials sponsored and "Boehringer Ingelheim"
with 1 trials sponsored. Other sponsors include -1 different institutions and
companies that sponsored additional 9 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "MGG Group Co., Inc., Chevy Chase Clinical Research"
#1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator and "Galapagos NV" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were
collaborators in the rest 3 trials.
Clinical Trials Conditions at MGG Group Co., Inc., Chevy Chase Clinical Research
According to Clinical.Site data, the most researched conditions in "MGG Group Co., Inc., Chevy Chase Clinical Research" are
"Ulcerative Colitis" (8 trials), "Crohn's Disease" (3 trials), "Chronic Idiopathic Constipation" (1 trials), "Colorectal Cancer" (1 trials) and "Colorectal Neoplasms" (1 trials). Many other conditions were trialed in "MGG Group Co., Inc., Chevy Chase Clinical Research" in a lesser frequency.
Clinical Trials Intervention Types at MGG Group Co., Inc., Chevy Chase Clinical Research
Most popular intervention types in "MGG Group Co., Inc., Chevy Chase Clinical Research" are "Drug" (15 trials) and "Device" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (7 trials), "Filgotinib" (4 trials), "PF-06651600" (2 trials), "PF-06700841" (2 trials) and "APT-1011" (1 trials). Other intervention names were less common.
Clinical Trials Genders at MGG Group Co., Inc., Chevy Chase Clinical Research
The vast majority of trials in "MGG Group Co., Inc., Chevy Chase Clinical Research" are
17 trials for "All" genders.
Clinical Trials Status at MGG Group Co., Inc., Chevy Chase Clinical Research
Currently, there are NaN active trials in "MGG Group Co., Inc., Chevy Chase Clinical Research".
undefined are not yet recruiting,
1 are recruiting,
2 are Active, not recruiting,
and 1 are Enrolling by invitation.
In total, there were 11 completed trials in MGG Group Co., Inc., Chevy Chase Clinical Research,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in MGG Group Co., Inc., Chevy Chase Clinical Research, 0 "Phase 1"
clinical trials were conducted, 5 "Phase 2" clinical
trials and 8 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 2 trials, and there were
also 1 trials that are defined as “Not Applicable".